logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
GSK
GSK plc
51.30
300 x undefined
700 x undefined
bid
ask
-
1.12
2.14%
500 @ 06:06 AM
52.21 +0.91 (1.77%)
Ytd4.61%
1y31.71%
51.08
day range
52.24
35.45
52 week range
61.70
Open52.20Prev Close52.42Low51.08High52.24Mkt Cap102.74B
Vol3.01MAvg Vol3.90MEPS3.75P/E13.68Forward P/E10.23
Beta0.29Short Ratio2.24Inst. Own18.86%DividendN/ADiv YieldN/A
Ex Div Date05-15Earning07-2850-d Avg51.65200-d Avg50.541yr Est56.63

GSK News

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
benzinga.com
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividen

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati

Is GSK Quietly Becoming An Oncology Powerhouse
seekingalpha.com
Is GSK Quietly Becoming An Oncology Powerhouse

GSK's dividend yield is 3.46%, which is higher than most Big Pharma players. GSK reaffirmed that its

GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs
benzinga.com
GSK, Spero Win FDA Nod For First-Ever Oral Carbapenem Antibiotic For Complicated UTIs

FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late
benzinga.com
GSK, Spero Therapeutics Announce FDA Approves Utebzi To Treat Complicated Urinary Tract Infections

https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult
benzinga.com
GSK's Exdensur Receives Canada Approval To Treat Severe Asthma, Chronic Rhinosinusitis With Nasal Po

GSK announced today that Health Canada has approved Exdensur (depemokimab) for two indications:As an

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
benzinga.com
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Y

During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst
benzinga.com
GSK's Momelotinib Receives Orphan Drug Designation From FDA And European Medicines Agency For VEXAS

GSK plc (LSE/NYSE:GSK) today announced that momelotinib, a JAK inhibitor with a differentiated mecha

Nasdaq 100 Tumbles Over 3%, Marvell Crashes 12%: Stock Market Today
benzinga.com
Nasdaq 100 Tumbles Over 3%, Marvell Crashes 12%: Stock Market Today

The Nasdaq 100 sank 3.3% Tuesday as AI and optical stocks cratered, while cash rotated into real est

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
benzinga.com
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuva

GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares su
benzinga.com
GSK Enters Agreement To Acquire Nuvalent For $10.6B At $124 Per Share, A 40% Premium To Last Closing

Multi-product oncology deal for assets that have validated targets and aim to address efficacy and/o